依折麦布联合辛伐他汀治疗急性冠状动脉综合征被引量：3

Combination Therapy of Ezetimibe with Simvastatin after Acute Coronary Syndromes

下载PDF

导出

摘要 1文献来源Cannon CP,Blazing MA,Giugliano RP,et al.The IMPROVE-IT investigators.Ezetimibe added to statin therapy after acute coronary syndromes[J].N Engl J Med,2015,372（25）：2387-2397.2证据水平1a。3背景低密度脂蛋白胆固醇（low-density lipoprotein,LDL-C）是动脉粥样硬化最重要的致病因素。

作者张成喜刘金来

机构地区中山大学附属第三医院心内科

出处《循证医学》 CSCD 2015年第6期348-351,共4页 The Journal of Evidence-Based Medicine

关键词急性冠状动脉综合征家族性高胆固醇血症依折麦布辛伐他汀 acute coronary syndrome familial hypercho-iesterolemia Ezetimibe Simvastatin

分类号 R541.4 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献6

1Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol- lowering treatment: Prospective meta- analysis of data from 90,056 participants in 14 randomised trials of statins [J]. Lancet, 2005, 366(9493) : 1267-1278.
2Davignon J. Beneficial cardiovascular pleiotropic effects of statins[J]. Circulation, 2004, 109(23 Suppl 1 ) : Ⅲ39-Ⅲ43.
3Landray M J, Haynes R, Hopewell JC, et al. Effects of extended -release niacin with laropiprant in high-risk patients [J]. N Engl J Med, 2014, 371(3) :203-212.
4Schwartz GG, Olsson AG, Abt M, et al. Effects of Dalcetrapib in patients with a recent acute coronary syndrome [J]. N Engl J Med, 2012, 367(22) : 2089-2099.
5Stone N J, Robinson JG, Lichtenstem AH, et al. 2013 ACU/ AHA guideline on the treatment of blood cholesterol to reduce athcrosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association task force on practice guidelines [ J ]. Circulation, 2014, 129 (25 Suppl 2) : S1-$45.
6无.选择性胆固醇吸收抑制剂临床应用中国专家共识（2015）[J].中华心血管病杂志,2015,43(5):394-398. 被引量：19

二级参考文献37

1王薇,赵冬,刘静,曾哲淳,孙佳艺,刘军,秦兰萍,吴兆苏.中国35～64岁人群胆固醇水平与10年心血管病发病危险的前瞻性研究[J].中华心血管病杂志,2006,34(2):169-173. 被引量：133
2The Collaborative Research Group for the Second Multi-center Survey of Clinical Management of Dyslipidemia in China.第二次中国临床血脂控制达标率及影响因素多中心协作研究[J].中华心血管病杂志,2007,35(5):420-427. 被引量：127
3武阳丰,赵冬,周北凡,王薇,李贤,刘静,李莹,孙佳艺,赵连成,吴兆苏,诸骏仁.中国成人血脂异常诊断和危险分层方案的研究[J].中华心血管病杂志,2007,35(5):428-433. 被引量：174
4Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S)[J]. Lancet, 1994, 344(8934): 1383-1389.6]BaigentC, BlackwellL, EmbersonJ, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials[J]. Lancet, 2010, 376(9753): 1670-1681.
5ZhaoS, WangY, MuY, et al. Prevalence of dyslipidaemia in patients treated with lipid-lowering agents in China: results of the dyslipidemia international study (DYSIS)[J]. Atherosclerosis, 2014, 235(2): 463-469.
6ZhaoSP, YuBL, PengDQ, et al. The effect of moderate-dose versus double-dose statins on patients with acute coronary syndrome in China: results of the CHILLAS trial[J]. Atherosclerosis, 2014, 233(2): 707-712.
7QiY, LiuJ, MaC, et al. Association between cholesterol synthesis/absorption markers and effects of cholesterol lowering by atorvastatin among patients with high risk of coronary heart disease[J]. J Lipid Res, 2013, 54(11): 3189-3197.
8Kes?niemiYA, MiettinenTA. Cholesterol absorption efficiency regulates plasma cholesterol level in the Finnish population[J]. Eur J Clin Invest, 1987, 17(5): 391-395.
9BurnettJR, HuffMW. Cholesterol absorption inhibitors as a therapeutic option for hypercholesterolaemia[J]. Expert Opin Investig Drugs, 2006, 15(11): 1337-1351.
10GrundySM, CleemanJI, MerzCN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel Ⅲ guidelines[J]. Circulation, 2004, 110(2): 227-239.